Hologic, Inc. (NASDAQ:HOLX) Receives Average Rating of “Hold” from Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have received a consensus rating of “Hold” from the nineteen ratings firms that are covering the stock, MarketBeat reports. Thirteen equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $79.7692.

A number of analysts have weighed in on the stock. Raymond James Financial lowered shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $78.00 price target on shares of Hologic in a report on Wednesday, October 22nd. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. UBS Group upped their price objective on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research report on Thursday, July 31st. Finally, Evercore ISI set a $78.00 target price on Hologic and gave the company an “outperform” rating in a research note on Tuesday, October 7th.

Insider Buying and Selling at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.88% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Allworth Financial LP raised its stake in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 216 shares during the last quarter. Xponance Inc. boosted its stake in shares of Hologic by 5.0% in the 1st quarter. Xponance Inc. now owns 35,726 shares of the medical equipment provider’s stock worth $2,207,000 after buying an additional 1,699 shares during the last quarter. Edgestream Partners L.P. bought a new stake in shares of Hologic in the first quarter worth $1,038,000. Massachusetts Financial Services Co. MA increased its position in Hologic by 11.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 49,209 shares of the medical equipment provider’s stock valued at $3,040,000 after acquiring an additional 4,918 shares during the last quarter. Finally, Leo Wealth LLC increased its position in Hologic by 25.5% during the first quarter. Leo Wealth LLC now owns 7,505 shares of the medical equipment provider’s stock valued at $464,000 after acquiring an additional 1,527 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 0.4%

Hologic stock opened at $74.60 on Wednesday. Hologic has a 12 month low of $51.90 and a 12 month high of $80.31. The company has a market capitalization of $16.59 billion, a price-to-earnings ratio of 30.95, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The business’s fifty day simple moving average is $69.29 and its two-hundred day simple moving average is $65.44. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.03. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the company earned $1.01 earnings per share. As a group, equities analysts predict that Hologic will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.